BiotechTube

GZ/SAR402671

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fabry Disease

Conditions

Fabry Disease

Trial Timeline

Jul 7, 2015 → Nov 20, 2018

NCT ID
NCT02489344

About GZ/SAR402671

GZ/SAR402671 is a phase 2 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02489344. Target conditions include Fabry Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02489344Phase 2Completed
NCT02228460Phase 2Completed

Competing Products

20 competing products in Fabry Disease

See all competitors
ProductCompanyStageHype Score
LucerastatIdorsiaPhase 3
72
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Venglustat (GZ402671) + PlaceboSanofiPhase 3
76
Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta)SanofiPhase 2
51
agalsidase betaSanofiApproved
84
TropicamideSanofiPre-clinical
22
Fabrazyme (agalsidase beta)SanofiApproved
84
agalsidase betaSanofiApproved
84
AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + FexofenadineSanofiApproved
84
Gabapentin + placeboSanofiPhase 2
51
Agalsidase betaSanofiApproved
84
GZ/SAR402671SanofiPhase 2
51
agalsidase beta (GZ419828) + agalsidase alfaSanofiApproved
84
Fabrazyme (agalsidase beta)SanofiPhase 3
76
Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + MigalastatSanofiPhase 3
76
IohexolSanofiPhase 1
32
Fabrazyme (agalsidase beta)SanofiPhase 2
51
Agalsidase betaSanofiApproved
84
Fabrazyme (agalsidase beta) + PlaceboSanofiApproved
84
Agalsidase beta + Agalsidase betaSanofiPhase 3
76

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84